Peptide News Digest

#BPC-157

93 stories

BPC-157 is a synthetic 15-amino-acid fragment derived from a gastric protein. It became one of the most-requested wellness peptides on the strength of rodent and lab studies of tendon, ligament, and gut repair.

The regulatory picture shifted on July 23, 2026. The FDA Pharmacy Compounding Advisory Committee (PCAC) voted 8-6 with 1 abstention to recommend adding BPC-157 to the Section 503A bulks list, overriding the June 29-30 FDA career-staff briefing documents that recommended against it. The vote is advisory, and formal rulemaking is still needed before compounding pharmacies can legally prepare BPC-157 under the 503A framework. In October 2026, The Washington Post reported a draft plan to allow temporary compounding while rules are written, and on October 14 the White House budget office received an FDA notice titled "Interim Access Policy for Compounding Using Certain Peptides." Neither is an approval. HHS released the policy on October 28: it will not take enforcement action against 503A pharmacies that compound BPC-157 and five other peptides, but the policy grants no FDA approval and does not change BPC-157's legal status.

The clinical evidence base remains thin. A 2026 STAT and Undark investigation found that nearly all of the roughly 200 BPC-157 studies on PubMed list Croatian researcher Predrag Sikiric or a close colleague as an author, the work carries undisclosed patent and commercial conflicts, and only three human studies have been published. See #pcac and #peptide-compounding for adjacent threads.

Regulatory · View digest

Health Canada Finds Sphingomonas Bacteria in an Injectable Peptide Seized From Ottawa's Sage & Summit Wellness Co.

Lab testing found Sphingomonas aquatilis/melonis bacteria in an injectable peptide product seized from Sage & Summit Wellness Co. at 451 Preston Street in Ottawa after a consumer complaint that the store sold unauthorized peptides in-store and online, Health Canada said on November 12. Products seized were labeled BPC-157, hCG, a BPC-157 and TB-500 "Healing Blend," KLOW (BPC-157, TB-500, GHK-Cu, and KPV), MOTS-C, Selank, Semax, Melanotan-1, retatrutide, and tesamorelin, plus oral BPC-157 capsules, and some vials were labeled "For Research Purposes Only." The store agreed to stop selling the products, and the agency told anyone who injected one and develops fever or swelling at the injection site to seek immediate medical care.

Clinical Trials · View digest

Hair-Thinning Trial Interim: Women Using a GHK-Cu, Thymulin, and BPC-157 Serum Reported Less Distress, With No Comparison Group Yet

In an interim, single-site analysis of a randomized trial in women aged 28 to 65 with androgenetic alopecia, 43 of 54 enrolled women had follow-up questionnaires after using a topical peptide serum (GHK-Cu, zinc thymulin, BPC-157) with an oral supplement gummy. Hair-related distress scores fell 24% after 3 months and 43% after 9 months on the products, and the share rating their hair loss as none or mild rose from 21% to 74% at 6 months, the abstract in SKIN: The Journal of Cutaneous Medicine reports. The authors say the unblinded, within-subject results describe patient experience rather than a demonstrated product effect, and hair-density data will come at the end of the study.

Industry · View digest

Hims & Hers Will Sell BPC-157 and TB-500 After HHS Eased Compounding Curbs, Starting With Sermorelin and Glutathione

Hims & Hers said on November 9 that it will begin selling glutathione, sermorelin, and NAD+ in November and will later offer BPC-157 and TB-500, the injury-recovery pair known as the "Wolverine stack," after HHS said last month that it would not take enforcement action against licensed pharmacies that compound them under certain conditions, Reuters reported. CEO Andrew Dudum said Hims would manufacture BPC-157 and TB-500 in the U.S.; Reuters noted that, like glutathione, the two have not been assessed by the FDA for safety or efficacy. CFO Yemi Okupe said revenue from the products is expected to be immaterial this year.

Research · View digest

Columbia Study of 300 Google Results on Orthopedic Peptides Finds Most Questions Ask How BPC-157 Works and What Its Risks Are

Orthopedic surgeons at NewYork-Presbyterian/Columbia ran three Google searches on peptide therapy in orthopedics, mainly BPC-157, and analyzed 300 "People also ask" questions and their linked websites. Structure and function (31.7%) and risks and complications (20.7%) were the top question topics, and websites averaged 2.0 of 4 on the JAMA benchmark criteria for source quality, with government sites (mostly PubMed articles) scoring 3.6 and medical practice and single-surgeon sites 0.7, the paper in Arthroscopy, Sports Medicine, and Rehabilitation reports. The authors advise doctors to discuss evidence quality when talking about peptides.

Industry · View digest

Escape Collective: Cyclists Are Injecting the BPC-157 and TB-500 "Wolverine Stack" for Injury Recovery

Durango, Colorado, cyclist Mark Gouge told Escape Collective he injected BPC-157 and TB-500 on a protocol from a riding friend after a second shoulder surgery this year and was back on his bike within six weeks, which he credits to the peptides. The cycling outlet reported on November 10 that such use is spreading through influencer promotion and gray-market sales, even though most popular peptides have not been approved for human use, have little rigorous human testing, and are banned in competitive sport.

Industry · View digest

SF Standard: Startup Accelerator's Peptide Party on a WWII Liberty Ship Handed Out CJC-1295 and Ipamorelin Strips

The San Francisco Standard reported on a black-tie, alcohol-free party hosted by the startup accelerator Haus Fund aboard the SS Jeremiah O'Brien at Pier 35, where guests signed waivers and sampled U.S.-made sublingual strips containing CJC-1295 and ipamorelin, a GHK-Cu cream, and products from Afterglow Science, whose strips include tirzepatide and a BPC-157, TB-500, and GHK-Cu blend. Guests received stickers reading "Buy American peptides"; Dr. Jordan Shlain, cofounder of a longevity medicine conference, said good manufacturing is no substitute for evidence, and the article notes little research supports claims that sublingual peptides absorb as well as injections.

Regulatory · View digest

NBC Bay Area: Santa Cruz Breast Cancer Survivor Who Injected BPC-157 From a Med Spa Warns Others After Her Cancer Returned

Paige Gordon told NBC Bay Area she bought an injectable "Glow Stack" containing BPC-157 from a nurse who ran an Aptos med spa, in January and was not told of any risks; she had been diagnosed with breast cancer about two and a half years ago, and the disease was found again about two months ago. The report notes there is no conclusive evidence BPC-157 contributed to her recurrence, and that concerns about peptides and tumor growth remain theoretical. It also covers HHS's October 28 policy allowing limited compounding of BPC-157 and five other unapproved peptides, which the Partnership for Safe Medicines' Shabbir Imber Safdar said the public has mistaken for an FDA approval.

Research · View digest

Clinical Notes Show Documented BPC-157 Use Rose 22-Fold From 2020 to 2025, but the Study Can't Credit Reported Benefits to the Peptide

Researchers at nference used a large language model, checked by physicians, to scan de-identified notes from a U.S. health-system network and confirmed BPC-157 use in 1,039 patients; newly documented users climbed from 23 in 2020 to 508 in 2025. When the source was recorded, it was usually a compounding pharmacy or gray-market vendor, and 56.6% of users also took other agents such as testosterone, NSAIDs, or TB-500. Improvement was noted for 79% of the 354 users with a recorded response, almost all of it patient-reported, and the authors write that the study establishes neither efficacy nor safety.

Regulatory · View digest

HHS Peptide Compounding Policy Published in the Federal Register, With Public Comments Open for Two Weeks

HHS published its enforcement discretion policy for 503A compounding with six peptide bulk substances in the Federal Register on October 30, 2026, under docket HHS-OASH-2026-0496, with written comments accepted for two weeks, through November 13. The notice calls the policy a draft and interim, says it is not binding, and says HHS may revisit it in whole or in part if a safety signal or product quality issue arises; FDA rulemaking on the 503A bulks list may later propose adding some or all of the peptides.

Regulatory · View digest

AP: HHS Dropped a Plan to Declare Six Peptides Safe for Compounding After FDA Scientists Refused to Back It

Citing six people familiar with the policy, the Associated Press reported that HHS first wanted the FDA to write a rule adding BPC-157 and other peptides to the list of substances safe for compounding, then switched to a promise not to enforce after agency scientists would not support it. FDA staff did get some safeguards added: ingredients from FDA-registered factories, side-effect reporting, and purity checks. Former FDA official Peter Lurie said the agency lacks the legal authority to enforce those pharmacy requirements.

Regulatory · View digest

HHS Will Let Compounding Pharmacies Make BPC-157, TB-500, and Four Other Unapproved Peptides Under a Temporary Policy

NPR reported Oct. 28 that HHS will not take enforcement action against small 503A compounding pharmacies that make BPC-157, TB-500, epitalon, KPV, MOTS-c, and semax. The policy is not an FDA approval and does not cover larger 503B outsourcing facilities; FDA scientists had recommended against lifting the restrictions in July. Public Citizen's Dr. Robert Steinbrook said Secretary Robert F. Kennedy Jr. "has undermined the FDA," while the president of a Florida compounding pharmacy told NPR, "We won't be able to meet demand."

Research · View digest

NYU Langone and Baptist Health Orthopedic Surgeons Find Human Evidence for BPC-157 in Muscles and Tendons Limited to One Small Case Series

Foot and ankle surgeons at NYU Langone Health and Baptist Health South Florida reviewed BPC-157, thymosin beta-4, and TB-500 in the Journal of the American Academy of Orthopaedic Surgeons on October 27, 2026. BPC-157 has the most animal data for tendon, ligament, muscle, and bone, but human musculoskeletal evidence is one small retrospective case series with no control group; thymosin beta-4's musculoskeletal data come only from lab and rodent studies, and TB-500, a seven-amino-acid fragment, is often confused with the full protein. None has an FDA-approved musculoskeletal use, and the authors advise against routine use and urge surgeons to ask about peptide use and warn athletes about anti-doping rules.

Regulatory · View digest

NSW Health Warns on Unapproved Peptides After 1,180 Emergency Visits, Rising From 5 a Month to Almost 220

New South Wales Health Minister Ryan Park warned on October 19, 2026 that 1,180 people attended NSW emergency departments after taking unapproved peptides between July 2025 and September 2026, with monthly presentations rising from 5 to almost 220, ABC News reported. NSW Health said unapproved products may contain BPC-157, GHK-Cu, TB-500, retatrutide, and CJC-1295, and Park cited liver and kidney damage, allergic reactions, and severe vomiting. He urged people to use only peptides prescribed by a doctor and dispensed by a pharmacy, and said the issue would likely go to other Australian health ministers.

Regulatory · View digest

HHS and FDA Send an 'Interim Access Policy for Compounding Using Certain Peptides' to the White House for Review

HHS and the FDA submitted an "interim access policy for compounding using certain peptides" to the White House Office of Management and Budget for review, according to a government filing reported by Reuters and the Associated Press on October 15, 2026. The filing gives no details, but AP, citing two people familiar with the plan, reported that it would let specialty compounding pharmacies temporarily make some popular peptides, including BPC-157, through enforcement discretion, meaning the FDA would choose not to act against them. Formally adding the peptides to the FDA's compounding list would still require rulemaking, and FDA staff scientists said in July that none had been studied enough to establish safety and effectiveness.

Regulatory · View digest

Washington Post: Administration Drafting a Plan to Let Some Restricted Peptides Be Sold Temporarily Through Compounding Pharmacies

The Washington Post reported on October 7, 2026, citing two people familiar with the matter, that the Trump administration is drafting plans to allow temporary sales of some previously restricted peptides while federal health officials write new rules for them; Reuters carried the report, and a summary of the article says the plan would cover seven peptides sold through compounding pharmacies. The plan had not been announced and could change. It follows the FDA advisory committee's July 2026 votes on peptides such as BPC-157; before those votes, FDA career scientists had said the evidence was too weak to support compounding them.

Regulatory · View digest

FDA Peptide Compounding Regulatory Status Continues Unchanged 46 Days After July PCAC Vote; No Proposed Rule, No Federal Register Notice

As of Tuesday September 8, 2026, the FDA has issued no proposed rule, no Federal Register notice, and no interim enforcement policy following the July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) 5-3 vote recommending six of seven candidate peptides — BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — for inclusion on the Section 503A Bulk Drug Substances List; emideltide (DSIP) was rejected. Forty-six days have passed since the meeting ended on July 24. Center for Drug Evaluation and Research warning-letter activity to compounding pharmacies has remained elevated through Q3 2026, and no acting-FDA-commissioner statement has updated the industry timeline. The February 2027 PCAC meeting to consider cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II, and PEG-MGF remains scheduled. Nominated FDA Commissioner Dr. Heidi Overton (August 19, 2026) continues to await Senate confirmation with Kyle Diamantas leading the agency in the interim. Formal FDA rulemaking to translate the PCAC recommendation into a proposed rule and then a final rule typically runs 12 to 24 months from PCAC vote; the interval of 46 days is within the normal window but longer than industry advocates had modeled at the meeting.

Regulatory · View digest

FDA Peptide Compounding Regulatory Limbo Continues 44 Days After July 24 PCAC Meeting; Still No Proposed Rule, No Federal Register Notice

As of Sunday September 6, 2026, the FDA has issued no proposed rule, no Federal Register notice, and no interim enforcement policy following the July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) vote to recommend six peptides — BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — for inclusion on the Section 503A Bulk Drug Substances List. The regulatory silence has now lasted 44 days since the meeting ended on July 24, and compounding pharmacies continue to operate in the gray zone that began with the April 22, 2026 removal of 12 peptides from Category 2. Center for Drug Evaluation and Research warning-letter activity to compounding pharmacies remained elevated through Q3 2026. The February 2027 PCAC meeting to consider cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II, and pegylated mechano growth factor (PEG-MGF) remains scheduled. Dr. Heidi Overton (nominated FDA Commissioner August 19, 2026) continues to await Senate confirmation. Formal FDA rulemaking to translate the July PCAC recommendation into a proposed rule and then a final rule typically runs 12 to 24 months from PCAC vote; the interval of just over six weeks is within the normal window but longer than industry advocates had modeled.

Regulatory · View digest

FDA Peptide Compounding Regulatory Limbo Enters Seventh Week Since July 23-24 PCAC Vote; No Proposed Rule, No Interim Enforcement Policy

As of Saturday September 5, 2026, the FDA has issued no proposed rule, no Federal Register notice, and no interim enforcement policy following the July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) vote to recommend six peptides — BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — for inclusion on the Section 503A Bulk Drug Substances List. The regulatory silence has now extended six weeks past the vote and continues to leave compounding pharmacies operating in the gray zone that began with the April 22, 2026 removal of 12 peptides from Category 2. Center for Drug Evaluation and Research warning-letter activity to compounding pharmacies has remained elevated through Q3 2026. The February 2027 PCAC meeting to consider cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II, and pegylated mechano growth factor (PEG-MGF) remains scheduled. Dr. Heidi Overton (nominated FDA Commissioner August 19, 2026) continues to await Senate confirmation with acting Commissioner Kyle Diamantas leading the agency through the interim.